Skip to Content
Merck
  • Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.

Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.

European journal of rheumatology and inflammation (1993-01-01)
R E Lister, D Acerbi, S Cadel
ABSTRACT

Piroxicam-beta-cyclodextrin is a novel NSAID; it is a supermolecular inclusion complex designed to improve the risk:benefit ratio of piroxicam. In animal studies it has been shown to be as effective as piroxicam as an anti-inflammatory and analgesic agent but with a more rapid onset of action and reduced gastropathic effects.

MATERIALS
Product Number
Brand
Product Description

USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Piroxicam, meets USP testing specifications
Sigma-Aldrich
Piroxicam, ≥98% (TLC)
Piroxicam, European Pharmacopoeia (EP) Reference Standard